BioPharma Dive October 12, 2021
Dive Brief:
- Takeda has gained access to as many as eight gene therapy programs through a freshly inked deal with the San Diego-based biotech Poseida Therapeutics.
- Per deal terms, the companies will use Poseida’s suite of genetic engineering technologies to develop up to six so-called in vivo programs, meaning the gene therapy does its work inside the body as opposed to in extracted cells. Takeda, which will provide funding for research and development, may also add two more programs to the collaboration.
- In exchange for its work, Poseida will receive $45 million up front along with preclinical research payments that could exceed $125 million, provided all six initial programs hit certain targets. Poseida could later take home up...
Today's Sponsors
Today's Sponsor